GREY:BIOAF - Post by User
Comment by
Boomskidon Jan 17, 2023 1:04pm
102 Views
Post# 35228452
RE:If you believe in xB3...
RE:If you believe in xB3...I wrote a piece about ten years ago about the commercial dangers of licensing diseases rather than therapeutics. No company should be able to buy an exclsive xB3 license for a disease.
I highly doubt that Midatech has THE answer for glioblastoma. The odds are simply against it.
The original payload for xB3-002 for glioblastoma was Avastin® (bevacizumab). Who knows what the ultimate solution may be? One thing for sure, xB3 should be available for any and all uniquely efficacious treatments for any disease, including glioblastoma.
If xB3 works as hoped, there are ethical considerations for its use. Inferior treatments can't be made into the best available treatments just because they can be exclusively transported across the BBB by xB3.
Such a strategy could delay the delivery of better drugs for years, and limit the owner of xB3 to the one solution rather than a suite of solutions, all earning revenue.
But like so many business concepts at Bioasis, this one was not exploited as a policy. It just faded away...
jd